IL135430A0 - Method and compositions for inducing tumor specific cytotoxicity - Google Patents

Method and compositions for inducing tumor specific cytotoxicity

Info

Publication number
IL135430A0
IL135430A0 IL13543098A IL13543098A IL135430A0 IL 135430 A0 IL135430 A0 IL 135430A0 IL 13543098 A IL13543098 A IL 13543098A IL 13543098 A IL13543098 A IL 13543098A IL 135430 A0 IL135430 A0 IL 135430A0
Authority
IL
Israel
Prior art keywords
compositions
tumor specific
specific cytotoxicity
inducing tumor
sequences
Prior art date
Application number
IL13543098A
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Publication of IL135430A0 publication Critical patent/IL135430A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to the specific expression of heterologous sequences, particularly genes encoding cytotoxic products, in tumor cells under the control of regulatory transcriptional sequences. Particularly preferred promoters include H19 regulatory sequences, the IGF-1 promoter and the IGF-2 P3 and P4 promoters. The invention provides expression constructs and methods of administering such expression constructs. The compositions and methods of the invention are useful in the treatment of cancer.
IL13543098A 1997-10-03 1998-10-04 Method and compositions for inducing tumor specific cytotoxicity IL135430A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94360897A 1997-10-03 1997-10-03
PCT/IL1998/000486 WO1999018195A2 (en) 1997-10-03 1998-10-04 Methods and compositions for inducing tumor-specific cytotoxicity

Publications (1)

Publication Number Publication Date
IL135430A0 true IL135430A0 (en) 2001-05-20

Family

ID=25479934

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13543098A IL135430A0 (en) 1997-10-03 1998-10-04 Method and compositions for inducing tumor specific cytotoxicity

Country Status (17)

Country Link
US (2) US6087164A (en)
EP (1) EP1019499B1 (en)
JP (3) JP5153031B2 (en)
KR (1) KR100524262B1 (en)
CN (1) CN1229496C (en)
AT (1) ATE407948T1 (en)
AU (1) AU755774B2 (en)
BR (1) BR9812717B1 (en)
CA (1) CA2308124C (en)
CZ (2) CZ294941B6 (en)
DE (1) DE69840001D1 (en)
HU (1) HU228470B1 (en)
IL (1) IL135430A0 (en)
NO (2) NO328470B1 (en)
PL (1) PL339949A1 (en)
RU (1) RU2214280C2 (en)
WO (1) WO1999018195A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006220A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of insulin-like growth factor 2 expression
US7041654B2 (en) * 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
DE19956568A1 (en) * 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
AU778737B2 (en) * 1999-04-14 2004-12-16 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
DE19928342A1 (en) * 1999-06-21 2000-12-28 Deutsches Krebsforsch New vector for tissue-specific expression, useful for treating tumors, contains gene for e.g. a cytotoxin under control of tissue-specific promoter and enhancer
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
WO2002046449A2 (en) * 2000-12-07 2002-06-13 The Penn State Research Foundation Selection of catalytic nucleic acids targeted to infectious agents
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US20040005567A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of cyclin-dependent kinase 4 expression
JPWO2003102186A1 (en) * 2002-05-31 2005-09-29 株式会社メディネット Cancer cell-specific expression-inducing DNA and cancer cell-specific expression vector
US20040180844A1 (en) * 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
US20040219099A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Method for the treatment of tumors
US20040220085A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Compositions for nucleic acid delivery
US7482156B2 (en) * 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof
US7063947B2 (en) * 2004-04-08 2006-06-20 Promogen, Inc. System for producing synthetic promoters
US7429482B2 (en) * 2005-01-13 2008-09-30 United States Of America As Represented By The Department Of Veterans Affairs Screening tools for discovery of novel anabolic agents
ES2435774T3 (en) 2005-07-07 2013-12-23 Yissum Research Development Company, Of The Hebrew University Of Jerusalem Nucleic acid agents for the negative regulation of H19, and methods of use thereof
US8034914B2 (en) 2005-09-22 2011-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
US7928083B2 (en) * 2007-01-16 2011-04-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem H19 silencing nucleic acid agents for treating rheumatoid arthritis
WO2009045370A2 (en) 2007-09-28 2009-04-09 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
CA2703774C (en) * 2007-10-25 2019-05-21 Avraham Hochberg Constructs containing multiple expression cassettes for cancer therapy
KR20110043580A (en) 2008-07-02 2011-04-27 가부시키가이샤 오츠까 세이야꾸 고죠 Artificial kidney precursor and process for production thereof
US8492133B2 (en) 2009-01-20 2013-07-23 Ramot At Tel Aviv University, Ltd. MIR-21 promoter driven targeted cancer therapy
EA016223B1 (en) * 2009-10-07 2012-03-30 Учреждение Российской Академии Наук Институт Молекулярной Генетики Ран Method and gene structure for high specific inhibiting of unwanted cell growth
CA2984879A1 (en) * 2015-05-05 2016-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Nucleic acid-cationic polymer compositions and methods of making and using the same
TWI808169B (en) * 2018-04-30 2023-07-11 美商阿米庫斯醫療股份有限公司 Gene therapy constructs and methods of use
CN110714075B (en) * 2018-07-13 2024-05-03 立森印迹诊断技术（无锡）有限公司 Grading model for detecting benign and malignant degrees of lung tumor and application thereof
CN111206093A (en) * 2018-11-21 2020-05-29 立森印迹诊断技术（无锡）有限公司 Marker for detecting invasive bladder cancer and application thereof
CN109609505A (en) * 2019-01-14 2019-04-12 中国科学院成都生物研究所 A kind of hammerhead ribozyme of the shearing RNA screened in vivo

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2699191B1 (en) * 1992-12-16 1995-02-10 Univ Paris Curie New retroviral vectors, cell lines containing them, and their use in the treatment of tumors.
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
IL108879A (en) * 1994-03-07 2000-08-31 Yissum Res Dev Co Diagnostic assay for malignancies using the H19 gene and kit
FR2723697B1 (en) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa METHOD OF TREATING RESTENOSIS WITH GENE THERAPY
FR2725213B1 (en) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa VIRAL VECTORS AND USE IN GENE THERAPY

Also Published As

Publication number Publication date
CA2308124C (en) 2008-07-08
BR9812717A (en) 2000-08-22
WO1999018195A3 (en) 1999-08-12
HUP0003745A2 (en) 2001-02-28
JP2006304801A (en) 2006-11-09
KR20010030912A (en) 2001-04-16
KR100524262B1 (en) 2005-10-28
NO20093194L (en) 2000-06-02
US6306833B1 (en) 2001-10-23
PL339949A1 (en) 2001-01-15
HUP0003745A3 (en) 2002-04-29
CZ294941B6 (en) 2005-04-13
BR9812717B1 (en) 2011-06-28
JP2001519148A (en) 2001-10-23
AU755774B2 (en) 2002-12-19
JP5153031B2 (en) 2013-02-27
AU9457198A (en) 1999-04-27
NO331723B1 (en) 2012-03-05
DE69840001D1 (en) 2008-10-23
NO328470B1 (en) 2010-02-22
CA2308124A1 (en) 1999-04-15
RU2214280C2 (en) 2003-10-20
US6087164A (en) 2000-07-11
JP2008136480A (en) 2008-06-19
ATE407948T1 (en) 2008-09-15
CN1229496C (en) 2005-11-30
NO20001684L (en) 2000-06-02
CZ294694B6 (en) 2005-02-16
WO1999018195A2 (en) 1999-04-15
CN1280616A (en) 2001-01-17
CZ20001201A3 (en) 2000-09-13
EP1019499B1 (en) 2008-09-10
NO20001684D0 (en) 2000-03-31
HU228470B1 (en) 2013-03-28
EP1019499A2 (en) 2000-07-19

Similar Documents

Publication Publication Date Title
IL135430A0 (en) Method and compositions for inducing tumor specific cytotoxicity
ZA935915B (en) Modified fungal cells and method for producing recombinant products
FI972225A0 (en) Tissue-specific replication vector
KR970000808B1 (en) Human proapolipoprotein a-1 expression
EP1308515A3 (en) Porcine factor VIII
WO1999064579A3 (en) Corn oleosin promoter and genes encoding corn desaturases
MX9705039A (en) Programmed cell death genes and proteins.
HK1030019A1 (en) Recombinational cloning using nucleic acids havingrecombination sites
PL314239A1 (en) Recombinated adenovirus vector and method of using it
HK1008347A1 (en) Dorsal tissue affecting factor and compositions
GR3024379T3 (en) Peptides with organo-protective activity, the process for preparing them and their use in therapy
IL126152A0 (en) Recombinant adenoviral vectors for human tumor gene therapy
ZA200202413B (en) Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression.
NZ303588A (en) Mpl ligand analogs having one or more changed glycosylation sites uses for these ligand analogs and dna sequences encoding them
EP0631474A4 (en) Cyclic anti-tumor promoter compounds, compositions and methods for production and use.
ZA981948B (en) Photodynamic Therapy Generated Oxidative Stress for Temporal and Selective Expression of Heterologous Genes.
WO2001081404A3 (en) INDUCIBLE PLASMID VECTOR ENCODING TGF-β AND USES THEREOF
WO1999042137A3 (en) Stress promoter control of therapeutic genes in gene therapy: compositions and methods
WO2000078939A3 (en) Vectors for the treatment of tumors by gene therapy
GB9312070D0 (en) Untranslated exon-1 sequences of eukaryotic genes as promoters
PL315670A1 (en) Expression of heterological proteins in attenuated bacteria with use of htra promoters
WO2001087934A3 (en) Treatment of neoplasia/transformation using a pituitary tumor transforming gene carboxy terminal peptides
MX9706483A (en) Methods and compositions for administering gene therapy vectors.
MX9801704A (en) Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed